Similar articles

• Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.

  Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, Janu A, Purandare N, Kumar R, More S, Goud S, Kadam N, Daware N, Bhattacharjee A, Shah S, Yadav A, Trivedi V, Behel V, Dutt A, Banavali SD, Prabhash K. Noronha V, et al. J Clin Oncol. 2020 Jan 10;38(2):124-136. doi: 10.1200/JCO.19.01154. Epub 2019 Aug 14. J Clin Oncol. 2020. PMID: 31411950 Clinical Trial.
• Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial.

  Han B, Jin B, Chu T, Niu Y, Dong Y, Xu J, Gu A, Zhong H, Wang H, Zhang X, Shi C, Zhang Y, Zhang W, Lou Y, Zhu L, Pei J. Han B, et al. Int J Cancer. 2017 Sep 15;141(6):1249-1256. doi: 10.1002/ijc.30806. Epub 2017 Jun 21. Int J Cancer. 2017. PMID: 28560853 Clinical Trial.
• A new standard for EGFR-mutant NSCLC?

  Killock D. Killock D. Nat Rev Clin Oncol. 2019 Oct;16(10):593. doi: 10.1038/s41571-019-0271-8. Nat Rev Clin Oncol. 2019. PMID: 31471565 No abstract available.
• Reply to T. Tanaka et al and F. Liang.

  Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Prabhash K. Noronha V, et al. J Clin Oncol. 2020 Mar 10;38(8):844-846. doi: 10.1200/JCO.19.02974. Epub 2020 Jan 2. J Clin Oncol. 2020. PMID: 31895609 No abstract available.
• Gefitinib (Iressa, ZD 1839) for non-small cell lung cancer (NSCLC): recents results and further strategies.

  Manegold C. Manegold C. Adv Exp Med Biol. 2003;532:247-52. doi: 10.1007/978-1-4615-0081-0_20. Adv Exp Med Biol. 2003. PMID: 12908563 Review.